Stock Evaluator: Vertex Pharmaceuticals Incorporated (VRTX)

654 followers

Vertex Pharmaceuticals Incorporated VRTX

$534.20 -3.59 -0.67%
November 17, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,511,447
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics VRTX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $136,352.6 $202.9 98%
Shares Out (Mil) 255.2 55.4 80%
Institutional Ownership 99.8% 92.9% 94%
Float (Mil) 252.8 40.7 77%
Beta 0.28 1.04 15%
Avg Daily Volume (000s) 1,443 566 74%
Price Change
(52-week)
23.8% 41.0% 73%
Growth VRTX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 14.1% 13.2% 71%
Net Income (5yr) 7.8% (10.3%) 52%
EPS (5yr) 8.3% 15.8% 44
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (28.8%) (15.7%) 21%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 21 25 25
Current EPS $4.102 $18.135 $19.917
Month Ago EPS $4.617 $18.664 $20.388
# Rev Up 0 1 0
# Rev Down 1 0 1
Three Months Ago EPS $4.916 $19.024 $21.816
Year/Year Chg 60.2% 18.4% 55.0%
Financials VRTX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $12,952 $39 86%
Net Income (TTM) (Mil) $3,976 ($44) 96%
EPS (TTM) $15.673 ($1.400) 97%
Operating Cash Flow (TTM) (Mil) $3,695 ($34) 93%
Net Cash Flow (TTM) (Mil) $41 ($1) 69%
Long-Term Debt (Q1) (Mil) $5,479 $4 86%
Enterprise Value (Q1) (Mil) $133,213 $144 97%
Valuation VRTX Industry
Median
Percentile
(All Stocks)
P/B 6.52 1.97 86%
P/E 34.6 17.5 78%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 4.2 0.8 85%
Ratios VRTX Industry
Median
Percentile
(All Stocks)
Gross Margin 54.8% 67.6% 67%
Net Margin 30.7% (50.6%) 89%
ROA 13.8% (47.4%) 92%
ROE 20.8% (53.5%) 80%
Liabilities to Assets 36.1% 29.7% 27%
F-Score 4 3 33%

Vertex Pharmaceuticals Incorporated did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors